Chemours Stock Price, News & Analysis (NYSE:CC)

Chemours trades on the New York Stock Exchange (NYSE) under the ticker symbol "CC."

Chemours declared a quarterly dividend on Wednesday, July 31st. Investors of record on Friday, August 16th will be paid a dividend of $0.25 per share on Monday, September 16th. This represents a $1.00 dividend on an annualized basis and a yield of 6.18%. The ex-dividend date of this dividend is Thursday, August 15th. View Chemours' Dividend History.

Chemours announced that its Board of Directors has approved a stock repurchase plan on Monday, December 4th 2017, which permits the company to repurchase $500,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to buy shares of its stock through open market purchases. Shares repurchase plans are usually a sign that the company's management believes its stock is undervalued.

Chemours Co (NYSE:CC) posted its quarterly earnings data on Thursday, August, 1st. The specialty chemicals company reported $0.72 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.90 by $0.18. The specialty chemicals company had revenue of $1.41 billion for the quarter, compared to the consensus estimate of $1.53 billion. Chemours had a net margin of 10.33% and a return on equity of 71.90%. The company's revenue was down 22.5% on a year-over-year basis. During the same period in the previous year, the company posted $1.71 earnings per share. View Chemours' Earnings History.

Chemours is scheduled to release their next quarterly earnings announcement on Thursday, November 7th 2019. View Earnings Estimates for Chemours.

Chemours updated its FY19 earnings guidance on Thursday, August, 1st. The company provided earnings per share (EPS) guidance of $2.37-3.08 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.88.

11 brokerages have issued twelve-month price objectives for Chemours' shares. Their forecasts range from $16.00 to $52.00. On average, they anticipate Chemours' stock price to reach $31.30 in the next year. This suggests a possible upside of 93.3% from the stock's current price. View Analyst Price Targets for Chemours.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chemours in the last year. There are currently 6 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Chemours.

Media coverage about CC stock has been trending somewhat negative this week, InfoTrie reports. The research firm rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Chemours earned a media sentiment score of -1.3 on InfoTrie's scale. They also gave media stories about the specialty chemicals company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Chemours.

Chemours saw a increase in short interest during the month of August. As of August 31st, there was short interest totalling 11,297,200 shares, an increase of 34.8% from the July 31st total of 8,381,000 shares. Based on an average daily volume of 3,220,000 shares, the days-to-cover ratio is currently 3.5 days. Approximately 7.0% of the company's shares are short sold. View Chemours' Current Options Chain.

Some companies that are related to Chemours include Johnson Matthey (JMPLY), Huntsman (HUN), Ashland Global (ASH), W. R. Grace & Co (GRA), KURARAY CO LTD/ADR (KURRY), Univar (UNVR), Ingevity (NGVT), Balchem (BCPC), Olin (OLN), Innospec (IOSP), PQ Group (PQG), GCP Applied Technologies (GCP), Innophos (IPHS), Loop Industries (LOOP) and Hawkins (HWKN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Chemours investors own include Micron Technology (MU), E I Du Pont De Nemours And Co (DD), NVIDIA (NVDA), DowDuPont (DWDP), Alibaba Group (BABA), Cisco Systems (CSCO), Johnson & Johnson (JNJ), AT&T (T), Intel (INTC) and Applied Materials (AMAT).

Chemours' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.85%), BlackRock Inc. (9.85%), Vanguard Group Inc. (9.48%), Third Point LLC (2.68%), LSV Asset Management (2.36%) and Bank of New York Mellon Corp (1.70%). Company insiders that own Chemours stock include Amy Trojanowski, Bradley J Bell, Christian W Siemer, David C Shelton, E Bryan Snell, Erich Parker, Mark Newman, Mark P Vergnano, Mary B Cranston, Paul Kirsch, Richard H Brown and Susan M Kelliher. View Institutional Ownership Trends for Chemours.

CC stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., BlackRock Inc., BlackRock Inc., Royal Bank of Canada, Schroder Investment Management Group, Schroder Investment Management Group, Parametric Portfolio Associates LLC and Bank of New York Mellon Corp. Company insiders that have sold Chemours company stock in the last year include Amy Trojanowski, Mark Newman and Paul Kirsch. View Insider Buying and Selling for Chemours.

CC stock was bought by a variety of institutional investors in the last quarter, including Third Point LLC, Invesco Ltd., Connor Clark & Lunn Investment Management Ltd., M&T Bank Corp, Morgan Stanley, WINTON GROUP Ltd, Nuveen Asset Management LLC and W.E. Donoghue & Co. LLC. Company insiders that have bought Chemours stock in the last two years include Bradley J Bell, David C Shelton, E Bryan Snell, Mark Newman, Mark P Vergnano, Mary B Cranston, Richard H Brown and Susan M Kelliher. View Insider Buying and Selling for Chemours.

Shares of CC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CC stock can currently be purchased for approximately $16.19.

Chemours has a market capitalization of $2.65 billion and generates $6.64 billion in revenue each year. The specialty chemicals company earns $995 million in net income (profit) each year or $5.67 on an earnings per share basis. Chemours employs 7,000 workers across the globe.View Additional Information About Chemours.

The official website for Chemours is http://www.chemours.com/.

Chemours' mailing address is 1007 MARKET STREET, WILMINGTON DE, 19899. The specialty chemicals company can be reached via phone at 302-773-1000 or via email at [email protected]